logo
Menu
Innovation Observatory > Reports > Cardiovascular Disease and Vascular Surgery

Results

Drugs

April 2018

Rivaroxaban for prevention of cardiovascular events following an episode of decompensated heart failure

Rivaroxaban is an oral medicine which prevents the development of blood clots by blocking the formation of a molecule called thrombin which is a key part of the process of blood clot formation. Rivaroxaban has the potential to reduce thrombin and blood clot formation in people with heart failure and coronary artery disease. This is potentially important as patients with heart failure after an episode of acute decompensation have been seen to have increased levels of thrombin. No other drug is currently licenced for use in this group of patients which targets thrombin.

Drugs

January 2018

PLX-PAD for Critical Limb Ischaemia (with minor tissue loss) in Patients Unsuitable for Revascularisation

Critical Limb Ischaemia (CLI) is a cardiovascular condition resulting in the deterioration of blood vessels that supply the muscles in the limb. In CLI, blockages within the arteries restrict the flow of blood to affected limbs – typically the lower extremities. Pain in the feet, toes, and/or legs ensues and further complications may include ulcers and gangrenous …

Drugs

November 2017

Rivaroxaban (Xarelto) in Combination with Aspirin for Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

Rivaroxaban and aspirin are drugs that reduce blood clots in blood vessels and are currently being given to some patients with CAD and PAD. The combination of rivaroxaban with aspirin is being developed as a more effective treatment.

Drugs

September 2017

Canakinumab (ILARIS®) for Cardiovascular risk reduction – Add on therapy

Cardiovascular disease (CVD) is a general term that refers to all conditions affecting the heart and blood vessels (circulation). These include angina, heart attack (also known as myocardial infarction), heart failure, stroke, and a number of diseases that affect the blood vessels. CVD is usually associated with a build-up of fatty deposits inside the blood …

Devices

March 2017

Magnetically-Enhanced Diffusion System for acute ischaemic stroke

The Magnetically-Enhanced Diffusion (MED) System™ in development by Pulse Therapeutics, Inc is designed to improve the delivery of thrombolytic therapy in people who have had an acute ischaemic stroke by using intravenously-injected iron nanoparticles and an externally positioned rotating magnetic field.

Drugs

February 2017

Anacetrapib in combination with a statin for patients with primary hypercholesterolaemia or mixed dyslipidaemia – adjunctive therapy

Anacetrapib is a new drug that may reduce the level of fats, like cholesterol, in your blood. High cholesterol can increase the risk of diseases such as heart attack and stroke, which are the main cause of death in the UK, accounting for over a quarter of all deaths each year. Anacetrapib is given as …

Drugs

November 2016

Evolocumab (Repatha) for cardiovascular event prevention – add on therapy

Evolocumab is a drug that may prevent cardiovascular events, such as heart attack or stroke, by reducing cholesterol. These diseases are the main cause of death in the UK, accounting for over a quarter of deaths each year. Evolocumab is given via an injection in combination with another drug (usually a statin) and changes to …

Drugs

November 2016

Bococizumab for primary hyperlipidaemia and mixed dyslipidaemia – adjunctive to statin therapy and/or diet

Bococizumab is a new drug to treat high levels of fat and cholesterol in the bloodstream (primary hyperlipidemia and mixed dyslipidemia). These conditions can cause a build-up of fatty deposits (plaques) in the arteries, which may lead to heart attacks and strokes. Bococizumab is given by subcutaneous injection. Some studies have suggested that this drug …

Diagnostics

October 2016

SMARTChip for early diagnosis of suspected stroke

SMARTChip is a point-of-care test to aid in the early diagnosis of stroke. It has been developed by Sarissa Biomedical Ltd. The test is intended for use in the emergency room and by paramedics on any patient satisfying the FAST (Face, Arms, Speech, Time) algorithm for suspected stroke. The assay uses a hand-held reader and …

Drugs

August 2016

Ticagrelor (Brilique) for peripheral arterial disease

Peripheral arterial disease is a common condition in which a build-up of fatty deposit in the arteries (atherosclerosis) restricts blood supply to leg muscles. Many people with peripheral arterial disease have no symptoms. However, some people develop a painful ache in their legs when they walk, which usually disappears after a few minutes’ rest. While …

Get Alerts